🇺🇸 FDA

Company profile · Sponsor

Arcus

Arcus Biosciences

RCUS · NYSE pharma HAYWARD, CA, USA
Pipeline
24
Drugs
0
Patents
8

Quick answer

Arcus (RCUS) is a pharma company. headquartered in HAYWARD, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker RCUS
Exchange NYSE
Company type pharma
Headquarters HAYWARD, CA, USA
SEC CIK 0001724521

Pipeline (24)

Search pipeline →

  1. CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, PLACEBO, CASDATIFAN

    Arcus

    Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  2. Casdatifan

    Arcus

    Metastatic Clear Cell Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  3. Domvanalimab

    Arcus

    Advanced Upper Gastrointestinal Tract Adenocarcinoma

    phase 3 small molecule active

    1 trial

  4. Durvalumab

    Arcus

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  5. FLUOROURACIL, CAPECITABINE, Zimberelimab, OXALIPLATIN, FLUOROURACIL, CALCIUM FOLINATE, DOMVANALIMAB, NIVOLUMAB, FLUOROURACIL, CAPECITABINE

    Arcus

    Metastatic Esophageal or Gastric Cancer, Esophageal or Gastric Cancer

    phase 3 small molecule active

    1 trial

  6. KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOMVANALIMAB, AB122 (Zimberelimab)

    Arcus

    Squamous Non-small cell Lung Cancer, Non-Small Cell Lung Cancer, Non squamous Non Small Cell Lung Cancer, Lung Cancer

    phase 3 small molecule active

    1 trial

  7. Quemliclustat

    Arcus

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  8. SALINE, GEMCITABINE, GEMCITABINE, Quemliclustat, GEMCITABINE, PACLITAXEL ALBUMIN-BOUND

    Arcus

    Pancreatic cancer, Metastatic Pancreatic ductal adenocarcinoma (mPDAC), Pancreatic ductal adenocarcinoma (PDAC)

    phase 3 small molecule active

    1 trial

  9. Volrustomig

    Arcus

    Advanced Clear Cell Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  10. Zimberelimab

    Arcus

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    2 trials

  11. AB680

    Arcus

    Metastatic Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  12. Atezolizumab

    Arcus

    Prostate Adenocarcinoma

    phase 2 small molecule active

    1 trial

  13. Casdatifan

    Arcus

    Renal Cell Carcinoma

    phase 2 small molecule active

    1 trial

  14. Domvanalimab

    Arcus

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  15. Domvanalimab

    Arcus

    Gastrointestinal Tract Malignancies

    phase 2 small molecule active

    1 trial

  16. Domvanalimab

    Arcus

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  17. Domvanalimab

    Arcus

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    2 trials

  18. Etrumadenant

    Arcus

    Prostatic Neoplasms, Castration-Resistant

    phase 2 small molecule completed

    1 trial

  19. Etrumadenant (AB928)

    Arcus

    Rectal Cancer

    phase 2 small molecule active

    1 trial

  20. Etrumadenant, Quemliclustat, FLUOROURACIL, BEVACIZUMAB, OXALIPLATIN, CALCIUM FOLINATE, Zimberelimab, Etrumadenant, REGORAFENIB

    Arcus

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  21. Fluorouracil

    Arcus

    Borderline Resectable Pancreatic Adenocarcinoma

    phase 2 small molecule active

    1 trial

  22. Gemcitabine

    Arcus

    Biliary Tract Carcinoma

    phase 2 small molecule active

    1 trial

  23. OXALIPLATIN, CALCIUM FOLINATE, Quemliclustat, Zimberelimab, FLUOROURACIL, DOMVANALIMAB

    Arcus

    Upper Gastrointestinal Tract Cancer, Advanced Upper Gastrointestinal Tract Malignancies, Gastrointestinal Tract Malignancies

    phase 2 small molecule active

    1 trial

  24. Quemliclustat

    Arcus

    Oligometastatic Prostate Cancer

    phase 2 small molecule active

    1 trial

Patents (8)

Search patents →

  1. US 12415854

    Antibodies to TIGIT

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12410170

    2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12384773

    Thiazole compounds and methods of use thereof

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12310965

    Treatment of cancer utilizing an identified adenosine fingerprint

    Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12281136

    Crystalline forms of a CD73 inhibitor and uses thereof

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12226425

    Inhibitors of ARG1 and/or ARG2

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12195447

    Azolopyrimidine for the treatment of cancer-related disorders

    Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12168023

    Inhibitors of adenosine 5′-nucleotidase

    Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Arcus?

Arcus (RCUS) is a pharma company. headquartered in HAYWARD, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Arcus sponsor?

We track 24 ClinicalTrials.gov-linked programs for Arcus, including CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, PLACEBO, CASDATIFAN and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Arcus company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.